Immunophotonics is results-driven

With over $3.35 million dollars invested in the development of inCVAX, Immunophotonics has completed required preclinical research, two 12 month off-shore pilot trials, and the regulatory development plan for the FDA. Our next major milestone is IND approval.

We are continuing to pursue additional financing opportunities to cover expenses related to FDA approval.

Immunophotonics management is committed to advancing our program quickly and efficiently while securing a significant return on investment to our investors. In order to sustain a compressed timeline for the FDA approval process (request accelerated approval and fast-track designation), the label of our development program will be end-stage patients that are refractory to other treatments.

If you are interested in learning more about Immunophotonics and our investment opportunities, please feel free to contact us by email (see below).